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Three major HIV vaccine efficacy clinical trials have now
been completed. Two failed, one of the two even increased
infection and the third was modestly successful. First: Vax-
Gen, used conventional gp120 protein and like in monkey
trials it failed likely due to type specific Abs and perhaps
inadequate Ab titans; the second, by the Vaccine Research
Center (VRC) and Merck based solely on CMI and predic-
tably failed. Less predictably it actually increased the num-
bers infected. This was likely due to use as a vector of an
adenovirus strain already exposed to a sizeable percentage
of people from earlier infections, thereby leading to
increased T-cell activation which is accompanied by an
increase in CCR5 co-receptor for HIV and consequently
to increased susceptibility to HIV infection. The third
large efficacy trial involved a novel gp120 delivered by the
canary pox virus known as ALVAC made by Sanofi as
well as some other HIV genes and boosted by a gp120
containing a herpes virus small sequence known as Gd.
This trial was run by Colonel Dr. Nelson Michael and his
co-workers in the U.S. Army AIDS research group in col-
laboration with colleagues in Thailand and resulted in
modest success associated with Abs (not CMI) which
binds V2 of gp120 and without detectable neutralizing Ab
activity. Of great interest to us was the short duration of
the Abs resulting in far greater success in the first half
year than in the remaining part of the study. This is typical
for Abs to gp120, and it is precisely what we have found in
our primate challenge experiments with our candidate
vaccine, a complex of gp120 with binding region of CD4
which we (A. DeVico, G. Lewis, T. Fouts, and Y. Guan)
call the full length single chain (FLSC).
I will summarize our rationale for the FLSC, our
updated primate results, and our plans for clinical trials
in collaboration with Sanofi, N. Michael and his group,
and the Gates Foundation.
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